CN101352454A - External-use gel foamable composition for gynecology inflammation and obesity - Google Patents
External-use gel foamable composition for gynecology inflammation and obesity Download PDFInfo
- Publication number
- CN101352454A CN101352454A CNA2008100131572A CN200810013157A CN101352454A CN 101352454 A CN101352454 A CN 101352454A CN A2008100131572 A CNA2008100131572 A CN A2008100131572A CN 200810013157 A CN200810013157 A CN 200810013157A CN 101352454 A CN101352454 A CN 101352454A
- Authority
- CN
- China
- Prior art keywords
- external
- foamable composition
- use gel
- sodium
- foaming agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a gel foaming agent used for treating gynecological inflammation and adiposity through external application. The gel foaming agent is composed of nano silver, weight-reducing medicine, a foaming agent, a transdermal absorption agent and an excipient. The invention describes the characters of the medicine such as formulation composition, preparation technique and disposable packaging. The gel foaming agent for external application can be applied on the skin or mucous membranes and has significant curative effects for treating vaginitis, cervicitis, cervical erosion, mixed infection type gynecological inflammation and adiposity; furthermore, the gel foaming agent for external application has great significance for popularization in industrial production.
Description
Technical field
The present invention relates to a kind of composition of medicine for the treatment of gynecological inflammation and obesity, specifically a kind of treat above-mentioned disease, be the external-use gel foamable composition that main component is made by nanometer silver and slimming medicine, and the industrialization production method and the application of this medicine.The technical field that belongs to medicine and preparation method thereof.
Background technology
Common gynecologic inflammation has: vaginitis, cervicitis, pelvic inflammatory disease, adnexitis etc.Normally because due to the infection of antibacterial or virus.Show that according to World Health Organization's latest survey report for the adult female, modal disease is not a flu, but reproductive tract infection; Modal malaise symptoms is not heating, headache etc., but the pruritus at secret place, abnormal flavour, pain etc.The probability that the adult female suffers from reproductive tract infection is 61%; The time that nearly 60% women took out 3-6 days every month is used for treating reproductive tract infection.Women crowd's health, work, life, happy family life in serious harm.At present, the medicine of treatment genital diseases is more on the market, and its main product is an antibiotic medicine.Life-time service is easy to generate Drug resistance and the home of destroying vagina.See from dosage form mostly to be oral medicine, suppository, washing liquid etc., so the general treatment effect is bad, treatment cycle is long, and the relapse rate height.
Obesity be meant the body fat overheap and (or) distribute unusually, the body constitution amount increases, and is a kind of multifactorial chronic metabolic disease.The improvement of material life condition and dietary structure unreasonable, obesity sickness rate are soaring year by year.Obesity not only influences figure and activity as a kind of whole body incretion metabolism disease, and closely related with hyperlipemia, atherosclerosis, hypertension, coronary heart disease, diabetes etc.Obesity has become a kind of global chronic disease of serious threat human health.The appetrol of Chu Shouing are of a great variety in the market, but the external use to lose weight medicine of percutaneous or mucosal drug delivery is not seen listing.
Positive effect of the present invention is, overcomes the deficiency of existing medicine, and a kind of external used medicine combination for the treatment of gynecological inflammation and obesity is provided.Women's daily pudendum health care and fat-reducing are combined; By vagina administration, reduce the untoward reaction and the toxic and side effects of medicine; Adopt the foam of dark foam manufacturing technology and non-returnable container preparation, be easy to the dispersion and the absorption of medicine, the convenient use; Gel of the present invention, be the macromolecular network system with semi-solid property, what it can the long period closely pastes with site of action, and better biocompatibility is arranged, and formed aquation gel layer after the gel imbibition has certain sustained release effect to medicine.Be applicable to the percutaneous or the mucosal drug delivery system of gynecological's antiinflammatory, fat-reducing.The preparation of above-mentioned innovative characteristics does not appear in the newspapers in patent retrieval.
Summary of the invention
One of purpose of the present invention provides the external used medicine combination of a kind of wide spectrum, efficient, safe treatment gynecological inflammation and obesity, especially has the gel foam agent medicine of slow-releasing.
Two of purpose of the present invention provides the industrialized producing technology of this gel foam agent medicine.
Further aim of the present invention provides the purposes of gel foam agent medicine.
Technical scheme of the present invention is achieved in that
A kind of external-use gel foamable composition for the treatment of gynecological inflammation and obesity, it is made up of nanometer silver antimicrobial colloid (or other antibacterial), slimming medicine, foaming agent, cutaneous permeable agent and excipient.
Described nanometer silver antimicrobial colloid is a particle diameter at 1-100nm, be uniformly distributed in and have antibacterial activity simple substance silver on the carrier material.About related contents such as the colloidal preparation of this nanometer silver antimicrobial, antibacterial mechanisms and characteristics, the patent that the inventor declared in 2007 " a kind of slowly-released type nanometer silver antibacterial gel and preparation method thereof and application ", application number: 200710011582.3 elaboration and claim are applicable to patent of the present invention;
Said other antibacterial comprise one or more in the elimination agent of beta-lactam antibiotic or fluorine-containing, chlorine, bromine, I;
Said slimming medicine, comprise chemosynthesis or natural drug in have one or more active component of antiobesity action, one or more combination in preferred Li Monaban (ACOMPLIA), sibutramine (sibtramine), orlistat (orlistat), eastern cloth Qu Ming, the Resina garciniae extract.
Said foaming agent is selected from the alkane derivative one or more combination, as sodium lauryl sulphate, sodium lauroyl sarcosine etc.
Said cutaneous permeable agent comprises that pharmaceutics allows the cutaneous permeable agent that uses.In preferred Herba Menthae, Borneolum Syntheticum, azone, the dimethyl sulfoxide one or more.
Said excipient is polyacrylic material or cellulosic material.Preferred carbomer, Polycarbophil, CBP and Polyethylene Glycol etc., or one or more combination wherein
Prescription of the present invention constitutes:
Nanometer silver 1-50 part, Li Monaban 0.1-50 part, sodium lauroyl sarcosine 10-200 part, sodium lauryl sulphate 10-100 part, coconut oil fatty acid monoethanolamide 10-150 part, tetrasodium ethylenediamine tetraacetate 1-10 part, sodium benzoate 1-5 part, sodium chloride 1-20 part, Borneolum Syntheticum 0.5-5g, Sodium Tvlose 1-15g, Borneolum Syntheticum 1-2 part, Mentholum 1-3 part, essence is an amount of, and pure water is an amount of.
The present invention preferably writes out a prescription to constitute:
Nanometer silver 1-20 part, Li Monaban 0.5-2 part, sodium lauroyl sarcosine 150-200 part, sodium lauryl sulphate 60-100 part, coconut oil fatty acid monoethanolamide 80-150 part, tetrasodium ethylenediamine tetraacetate 2-5 part, sodium benzoate 2-5 part, sodium chloride 5-10 part, Borneolum Syntheticum 0.5-2g, Sodium Tvlose 5-10g, Borneolum Syntheticum 1-2 part, Mentholum 1-3 part, essence is an amount of, and pure water is an amount of.
Technological process of the present invention: it is to adopt existing gel foam preparation technique to realize.It is an independent packaging unit that its inner packing adopts a drug dose.Concrete technology: with sodium lauroyl sarcosine, sodium lauryl sulphate, tetrasodium ethylenediamine tetraacetate, sodium benzoate add in the deionized water, high-speed stirred Hybrid Heating to 70 degree heating for dissolving; Coconut oil fatty acid monoethanolamide is added in the deionized water, and heating for dissolving expands; Borneolum Syntheticum is pulverized, used dissolve with ethanol respectively with Mentholum.Above-mentioned solution merges, and successively with nanometer silver, Li Monaban, sodium chloride join in the solution, fully stirs, and transfers PH6.0-7.0 with calcium hydroxide, packing, quality inspection, dispatches from the factory.
Intention novelty of the present invention constitutes simply, and cost is moderate, is applicable to the big popularization of producing of industry.Product of the present invention is mainly used in the women and treats all kinds of vaginitiss, cervicitis, cervical erosion, leucorrhea abnormal etc., improves the vagina self-cleaning function; And effectively regulate the metabolic balance of body, the bodily form of keeping fit is realized health slimming.
The specific embodiment
In conjunction with experimental data, be described in detail the specific embodiment of the present invention.Cited embodiment is in order to help those skilled in the art more fully to understand the present invention.But the right that does not limit the present invention in any way.
Embodiment one:
Prescription is formed:
16 parts of nanometer silvers, 1.6 parts of Li Monaban, 150 parts of sodium lauroyl sarcosines, 60 parts of sodium lauryl sulphates, 80 parts of coconut oil fatty acid monoethanolamides, 5 parts of tetrasodium ethylenediamine tetraacetates, 3 parts of sodium benzoate, 8 parts in sodium chloride, Sodium Tvlose 5-10g, Borneolum Syntheticum 2g,, Mentholum 1-3 part, essence is an amount of, and pure water is an amount of.Make 1000g.
Preparation technology:
1, with sodium lauroyl sarcosine, sodium lauryl sulphate, tetrasodium ethylenediamine tetraacetate, sodium benzoate add in the deionized water, and high-speed stirred Hybrid Heating to 70 degree heating for dissolving gets A solution.
2, coconut oil fatty acid monoethanolamide is added in the deionized water, heating for dissolving expands, and gets B solution
3, B solution is under agitation slowly added A solution, stir, get C solution.
4, Borneolum Syntheticum is pulverized, used dissolve with ethanol respectively, get D solution with Mentholum.
5, the C solution stirring is cooled to 30 degree, successively with nanometer silver, Li Monaban, sodium chloride, D solution join in the C solution, fully stir,
6, transfer PH6.0-7.0 with calcium hydroxide,
7, with the plastics injector fill of manufactured goods with the composite sanitary standard, every 3-4g.
Embodiment two:
Prescription is formed:
10 parts of nanometer silvers, 2 parts of sibutramine, 200 parts of sodium lauroyl sarcosines, 90 parts of sodium lauryl sulphates, 100 parts of coconut oil fatty acid monoethanolamides, 3 parts of tetrasodium ethylenediamine tetraacetates, 3 parts of sodium benzoate, 8 parts in sodium chloride, Acritamer 940 10g, Borneolum Syntheticum 2g, Mentholum 1-3 part, essence is an amount of, pure water is an amount of.
Preparation technology:
Preparation method is with embodiment one.
Effect example one: in-vitro antibacterial experimental result of the present invention
To escherichia coli bacteriostatic experiment result
Annotate: the equal asepsis growth of negative control group
To Candida albicans bacteriostatic experiment result
Annotate: the equal asepsis growth of negative control group
Above experimental result is provided by Liaoning Province Center for Disease Control (CDC)
Effect example two:
External of the present invention is to colpitic therapeutic outcome
Claims (10)
1, a kind of external-use gel foamable composition for the treatment of gynecological inflammation and obesity.It is characterized in that: described external-use gel foamable composition, it is made up of nanometer silver antimicrobial colloid (or other antibacterial), slimming medicine, foaming agent, cutaneous permeable agent and excipient.The external used medicine that is prepared from through specific process.
2, the described nanometer silver antimicrobial colloid of claim 1.It is characterized in that: described nanometer silver antimicrobial colloid be particle diameter at 1-100nm, be uniformly distributed on the carrier material, have antibacterial activity simple substance silver.
3, described other antibacterial of claim 1 is characterized in that: said other antibacterial comprise one or more in the elimination agent of beta-lactam antibiotic or fluorine-containing, chlorine, bromine, I.
4, the described slimming medicine of claim 1 is characterized in that: said slimming medicine, comprise chemosynthesis or natural drug in have one or more active component of antiobesity action.One or more combination in preferred Li Monaban (ACOMPLIA), sibutramine (sibtramine), orlistat (orlistat), eastern cloth Qu Ming, the Resina garciniae extract.
5, the described said foaming agent of claim 1, it is characterized in that: said foaming agent is the combination of one or more active component in the alkane derivative, as sodium lauryl sulphate, sodium lauroyl sarcosine etc.
6, the described said cutaneous permeable agent of claim 1 is characterized in that: said cutaneous permeable agent comprises that pharmaceutics allows the cutaneous permeable agent that uses.In preferred Herba Menthae, Borneolum Syntheticum, azone, the dimethyl sulfoxide one or more.
7, the described said excipient of claim 1 is characterized in that: said excipient is polyacrylic material or cellulosic material.Preferred carbomer, Polycarbophil, CBP and Polyethylene Glycol etc., or one or more combination wherein
8, the described said external-use gel foamable composition of claim 1, it is characterized in that: said external-use gel foamable composition prescription formation is: nanometer silver 1-20 part, Li Monaban 0.5-2 part, sodium lauroyl sarcosine 150-200 part, sodium lauryl sulphate 60-100 part, coconut oil fatty acid monoethanolamide 80-150 part, tetrasodium ethylenediamine tetraacetate 2-5 part, sodium benzoate 2-5 part, sodium chloride 5-10 part, Borneolum Syntheticum 0.5-2g, Sodium Tvlose 5-10g, Borneolum Syntheticum 1-2 part, Mentholum 1-3 part, essence is an amount of, and pure water is an amount of.
9, the specific process of the described external-use gel foamable composition of claim 1 is characterized in that: it is to adopt existing gel foam preparation technique to realize.It is an independent packaging unit that its inner packing adopts a drug dose.
10, the purposes of the described external-use gel foamable composition of claim 1.It is characterized in that: described external-use gel foamable composition is used for the treatment of all kinds of vaginitiss, cervicitis, cervical erosion, leucorrhea abnormal etc.; Effectively regulate the metabolic balance of body, the bodily form of keeping fit is realized health slimming.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008100131572A CN101352454A (en) | 2008-09-11 | 2008-09-11 | External-use gel foamable composition for gynecology inflammation and obesity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008100131572A CN101352454A (en) | 2008-09-11 | 2008-09-11 | External-use gel foamable composition for gynecology inflammation and obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101352454A true CN101352454A (en) | 2009-01-28 |
Family
ID=40305627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008100131572A Pending CN101352454A (en) | 2008-09-11 | 2008-09-11 | External-use gel foamable composition for gynecology inflammation and obesity |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101352454A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102872160A (en) * | 2012-10-26 | 2013-01-16 | 广东同德药业有限公司 | Nano-silver foaming agent used for sterilizing wounds of scalds and burns and ulcer wounds |
EP4101467A4 (en) * | 2020-02-05 | 2024-03-06 | NOF Corporation | Agent for treating or preventing pancreatic fistula |
-
2008
- 2008-09-11 CN CNA2008100131572A patent/CN101352454A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102872160A (en) * | 2012-10-26 | 2013-01-16 | 广东同德药业有限公司 | Nano-silver foaming agent used for sterilizing wounds of scalds and burns and ulcer wounds |
EP4101467A4 (en) * | 2020-02-05 | 2024-03-06 | NOF Corporation | Agent for treating or preventing pancreatic fistula |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1872026A (en) | New medicinal preparation for vagina | |
CN100457084C (en) | Nanometer silver type external use antibiotic gel for female external use and its prepn. method | |
CN101062055A (en) | Slowly-released type nanometer silver antibacterial gel and the preparing method and the application thereof | |
CN1141929C (en) | Medicament and method of treating an organism with medicaments | |
CN105640916A (en) | Povidone iodine effervescent tablets with anti-microbial, skin-care and anti-inflammation functions and production process of povidone iodine effervescent tablets | |
CN101683316B (en) | Temperature responsive bio-adhesive in situ gel sustained-release preparation for vagina | |
CN101524544A (en) | Composite gel film agent | |
CN101401862A (en) | External-use gelling agent for treating cervical erosion | |
CN101352454A (en) | External-use gel foamable composition for gynecology inflammation and obesity | |
CN104667259A (en) | Medicinal composition capsule for treating chronic constipation and preparation method thereof | |
CN101088505B (en) | Nanometer breviscapine polymer particle preparation and its preparation process | |
CN103520262B (en) | A kind of lipid soluble gynecological gel | |
CN102100751A (en) | Preparation technology of new integrative formulation of largetrifoliolious bugbane rhizome and kudzuvine root decoction and production method thereof | |
CN1672689A (en) | Nano silver antiseptic gel for treating women's genital tract infection and its prepn and application | |
CN1099282C (en) | Foaming medicine for treating gynopathy and preparing process thereof | |
CN102283928A (en) | Technology for preparing novel integrated dosage form of Ermiao powder and production method thereof | |
CA2271657C (en) | Androgen as a male contraceptive and non-contraceptive androgen replacement | |
CN102648922A (en) | Gamuzhuer medicinal latex preparation and preparation method thereof | |
CN102284018A (en) | Technology for preparing novel oyster shell powder integral preparation and production method thereof | |
CN101912376A (en) | Matrine vaginal effervescent tablets with bilayer structure and preparation method | |
CN100450484C (en) | Imiquimod turbid liquor and gelling agent thereof | |
CN108186705A (en) | A kind of anti-inflammatory gelling agent and preparation method thereof | |
CN102100662A (en) | Integrative novel preparation theory of medicines and production method thereof | |
CN102552595A (en) | Siqitang integrated novel dosage form and production method thereof | |
CN100571713C (en) | The new purposes of silver peroxide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090128 |